Karen Jacobs, DO
Family Medicine · Wimauma, FLNPI 1346338316
Payments from drug & device makers
Across 138 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$415
- AbbVie$312
- Lilly USA, LLC$212
- AstraZeneca$197
- Amgen$178
- Bayer$146
- plus $949 from 18 others
What the payments were for
- Food & beverage$2,37699%
- Education$331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $415 |
| AbbVie(2 entities) | 16 | $312 |
| Lilly USA, LLC | 14 | $212 |
| AstraZeneca | 13 | $197 |
| Amgen | 11 | $178 |
| Bayer | 6 | $146 |
| Boehringer Ingelheim | 6 | $111 |
| Exact Sciences | 6 | $106 |
| Merck | 6 | $96 |
| GSK | 6 | $96 |
| Pfizer | 4 | $85 |
| Abbott | 4 | $84 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $64 |
| Johnson & Johnson | 3 | $54 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Mylan Specialty L.p. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $37 |
| Nevro Corp. | 1 | $23 |
| Boston Scientific | 1 | $19 |
| Seqirus USA Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Novartis | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$2,409 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 128 | $178,011 |
| JardianceEmpagliflozin | 97 | $132,037 |
| TrulicityDulaglutide | 58 | $89,241 |
| EliquisApixaban | 61 | $83,358 |
| XareltoRivaroxaban | 50 | $70,293 |
| MounjaroTirzepatide | 44 | $55,240 |
| FarxigaDapagliflozin Propanediol | 30 | $40,913 |
| MyrbetriqMirabegron | 35 | $28,293 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $22,206 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $20,060 |
| Bydureon BciseExenatide Microspheres | 17 | $17,205 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $16,054 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $15,217 |
| Repatha SureclickEvolocumab | 15 | $14,350 |
| JanuviaSitagliptin Phosphate | 11 | $12,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $415 | $178,011128 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $212 | $144,481102 claims |
| Boehringer IngelheimJardiance | $111 | $132,03797 claims |
| PfizerEliquis | $85 | $83,35861 claims |
| Johnson & JohnsonXarelto | $54 | $70,29350 claims |
| AstraZenecaFarxiga, Symbicort | $197 | $43,60343 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $96 | $38,26038 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $28,29335 claims |
| MerckJanuvia | $96 | $12,78411 claims |
| AbbVieSynthroid | $312 | $2,85250 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Wimauma
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.